NEW YORK, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, today announced the change of its OTCQB trading symbol from AHLL to EMBT. The change will take effect on February 24, 2016.
The new trading symbol, which is more closely aligned with the Company’s name, is intended to strengthen the Ember Therapeutics brand and increase its profile within the investment community.
Beginning February 24, 2016 all information, including stock trading, SEC filings, and market data related to Ember Therapeutics, will be reported under the new ticker symbol, “EMBT.” The CUSIP for company’s common stock will remain unchanged. Outstanding stock certificates are not affected by the symbol change and will not need to be exchanged.
About Bone Morphogenetic Protein-7 (BMP-7)
BMPs are a group of growth factors also known as cytokines and as metabologens. Originally discovered by their ability to induce the formation of bone and cartilage, BMPs are now considered to constitute a group of pivotal morphogenetic signals, orchestrating tissue architecture throughout the body. For example, previous studies have demonstrated that BMP-7 can facilitate effective joint cartilage formation, inhibit and reverse organ fibrosis in the kidney, heart, and lung due to injury or disease, and diabetic diseases related to glucose metabolism.
About Ember Therapeutics, Inc.
Ember Therapeutics, Inc. is a clinical stage biopharmaceutical company whose primary focus is on utilizing Bone Morphogenetic Protein-7 to catalyze cartilage regeneration for disease modification of Osteoarthritis (OA) and the inhibition and reversal of organ fibrosis in diseases such as Chronic Kidney Disease (CKD) and Alport Syndrome. In particular, Ember has acquired over 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and cGMP manufactured material from Stryker Corporation. For more information, please visit www.embertx.com.
Ember Therapeutics Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Ember Therapeutics’ business and Ember Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contact The Ruth Group Lee Roth email@example.com (646) 536-7012
Source: Ember Therapeutics